NUNaoto T. Ueno

Naoto T. Ueno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Naoto T. Ueno has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Ana M. Gonzalez-Angulo

    The University of Texas MD Anderson Cancer Center, Houston, TX

    1 shared publication
  • Chandra Bartholomeusz

    Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, USA

    1 shared publication
  • Fanny Le Du

    The University of Texas MD Anderson Cancer Center, Houston, TX

    1 shared publication
  • Gabriel N. Hortobagyi

    Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, USA

    1 shared publication
  • Gabriel N. Hortobagyi

    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA

    1 shared publication
  • Jangsoon Lee

    Section of Translational Breast Cancer Research, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    1 shared publication

Latest Publications

  • A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression

    by Jangsoon Lee, Chandra Bartholomeusz, Oula Mansour, Juliane Humphries, Gabriel N. Hortobagyi, Peter Ordentlich, Naoto T. Ueno

    Although there are effective HER2-targeted agents, novel combination strategies in HER2-overexpressing breast cancers are needed for patients whose tumors develop drug resistance. To develop new therapeutic strategy, we investigated the combinational effect of entinostat, an oral isoform-selective histone deacetylase type I inhibitor, and lapatinib, a HER2/EGFR dual tyrosine kinase inhibitor, in HER2+ breast cancer cells. We assessed the combinational synergistic effect and its mechanism by CellTiter Blue assay, flow cytometry, anchorage-independent growth, quantitative real-time PCR, small interfering RNA, Western blotting, and mammary fat pad xenograft mouse models. We found that compared with entinostat or lapatinib alone, the two drugs in combination synergistically inhibited proliferation (P < 0.001), reduced in vitro colony formation (P < 0.05), and resulted in significant in vivo tumor shrinkage or growth inhibition in two xenograft mouse models (BT474 and SUM190, P < 0.001). The synergistic anti-tumor activity of the entinostat/lapatinib combination was due to downregulation of phosphorylated Akt, which activated transcriptional activity of FOXO3, resulting in induction of Bim1 (a BH3 domain-containing pro-apoptotic protein). Furthermore, entinostat sensitized trastuzumab/lapatinib-resistance-HER2-overexpressing cells to the trastuzumab/lapatinib combination and enhanced the anti-proliferation effect compare with single or double combination treatment. This study provides evidence that entinostat has enhanced anti-tumor effect in combination with HER2-targeted reagent, lapatinib, and resulting in induction of apoptosis by FOXO3-mediated Bim1 expression. Our finding justifies for conducting a clinical trial of combinational treatment with entinostat, lapatinib, and trastuzumab in patients with HER2-overexpressing breast cancer resistant to trastuzumab-based treatment.


  • Impact of 21-gene RT-PCR assay on adjuvant therapy for stage I breast cancer.

    by Fanny Le Du, Richard L. Theriault, Jie S. Willey, Vicente Valero, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo, Naoto T. Ueno

    586 Background: A recurrence score (RS) derived from a 21-gene RT-PCR assay (Oncotype DX) stratifies patients (pts) with early estrogen receptor (ER)-positive, HER2-normal breast cancer (BC) into 3 groups based on risk of 10-year distant metastasis rate: low, intermediate, and high. High RS predicts benefit from chemotherapy follow-by hormonal therapy (CH-T); whether intermediate RS predicts benefit from CH-T is unknown. For Stage I, NCCN Clinical Practice Guidelines recommend use of RS for T1b BC with unfavorable features (angiolymphatic invasion, high histologic or nuclear grade) and T1c BC. However, data are limited on how RS influences treatment of stage I BC. We sought to define the impact of RS on treatment in pts with stage I BC. Methods: In 1057 pts with ER-positive, HER2-normal stage I BC with RS available, we assessed the interaction between RS and treatment by tumor category. Kaplan-Meier survival curves and log-ranktests were used to compare outcomes. Results: Pts with T1a, T1b, and T1c BC did not differ in the distribution of low, intermediate and high RS (P=0.53) (Table). In the T1b and T1c groups, 57% and 52%, respectively, of pts with intermediate RS did not receive chemotherapy. Median follow-up is 25.7 months. Among T1b pts with intermediate RS, disease-free survival did not differ between pts who received HT and those who received CH-T (P=0.84). Among T1b pts with intermediate RS, pts who received CH-T had higher RS than pts who received HT (median 23 vs 21, P<0.001). Conclusions: Less than 10% of patients with stage I had high RS.More than half of pts with stage I BC and intermediate RS received HT alone. Pts with higher RS were more likely to receive CH-T. Among pts with T1b BC and intermediate RS, pts who received HT alone had the similar DFS as those who received CH-T.